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ABSTRACT
Blastoschizomyces capitatus, Scedosporium proliﬁcans and S. apiospermum are emerging fungal pathogens
that may cause disseminated disease in neutropenic patients. They can present as fever resistant to
antibiotics and to wide-spectrum antifungal agents, although they may involve almost every organ. The
proportion of recovery from blood cultures is high and they are characteristically resistant to most
antifungal agents. Prognosis is poor unless patients recover from neutropenia. Voriconazole has good
in-vitro activity and is currently the drug of choice for these infections.
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BLASTOSCHIZOMYCES CAPITATUS
The fungus known as Blastoschizomyces capitatus
was previously known as Trichosporon capitatum,
Geotrichum capitatum and Blastoschizomyces pseu-
dotrichosporom, and was considered a new genus
in 1985 after the suggestion by Salkin and
colleagues [1]. It is a yeast-like fungus that forms
creamy, wrinkled colonies and grows in conven-
tional media, including Sabouraud, but which is
resistant to cycloheximide. Its principal charac-
teristic is the production of annelloconidia
which, after schizogonic division, develop struc-
tures similar to arthroconidia. It can be identiﬁed
by conventional commercial products, it is inca-
pable of using potassium nitrate as its only
source of nitrogen and it is incapable of assimil-
ating a large number of carbohydrates. B. capitatus
has been characterised by molecular methods
and differentiated from similar fungi [2–4].
Epidemiology
B. capitatus can be isolated in nature and the
environment and is capable of colonising the
mucosa and the skin of some patients. It was
not considered as a pathogenic fungus until 25
years ago. It has been isolated in sputum, faeces,
oral mucosa, skin and liquids for intravenous infu-
sion as well as in environmental samples [5–10].
It is a potential cause of mastitis in cattle [11].
In a study involving 353 immunocompromised
patients, the presence of colonisation and infec-
tion by B. capitatus was sought over a 37-month
period. Thirteen (3.7%) cases had developed
colonies in stool, skin, or urine and three of these
13 developed systemic infection [12].
B. capitatus can produce dermatomycosis, onyc-
homycosis [13–15] and some deep localised
lesions, but its greatest danger lies in its capacity
to cause disseminated and invasive mycoses, par-
ticularly in severely immunodepressed patients.
Neutropenia is the most important predisposing
factor, followed by the use of corticosteroids and
other immunodepressors.
Experimental models were obtained initially in
rabbits and later in other animals, including
irradiated mice, in which heart and kidney
abscesses appeared relatively easily after intra-
venous infusion [6,16,17].
Correspondence and reprint requests: E. Bouza, Servicio de
Microbiologı´a Clı´nica y E. Infecciosas, Hospital General
Universitario ‘Gregorio Maran˜o´n, Dr Esquerdo 46, 28007,
Madrid, Spain
Tel: + 34 91 5868452
Fax: + 34 91 3721721
E-mail: ebouza@microb.net
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
In one of the most important series, published
by Martino et al. [8], the authors report 21 patients
over a 30-month period, of whom 12 were
infected, four were possibly infected and ﬁve
were colonised.
The invasive and disseminated disease almost
only affects patients with haematological disor-
ders, who are undergoing chemotherapy during
periods of profound neutropenia. It usually pre-
sents with fever, and is generally resistant to
antibiotics and sometimes to antifungals such as
azole derivatives or amphotericin B. It can present
with cutaneous lesions, sometimes in the form of
a disseminated maculo-papular rash, or it can
appear with catheter-related sepsis or focal
lesions [8].
Other clinical manifestations can include
cough, expectoration, chest pain, spontaneous
pneumothorax, pulmonary inﬁltrates and jaun-
dice. In some patients with hepatosplenic involve-
ment it cannot be distinguished clinically from
hepatosplenic candidiasis [8,18,19].
It has been reported as a pulmonary pathogen
[6] and also as affecting the gastrointestinal tract
[20], kidney and liver [8,21] (Fig. 1).
It can present by invading the central nervous
system, either in the form of localised lesions or as
meningitis or encephalitis [22].
Occasionally, it presents with endocarditis,
generally in disseminated disease in the neutrop-
enic patient, but also as a disease which appears
to have been contracted in the operating theatre in
immunodepressed patients undergoing valve
replacement with extracorporeal surgery
[3,8,23,24].
As far as osteoarticular manifestations are
concerned, B. capitatus has been described as a
cause of mandibular osteomyelitis in a patient
with lymphoma [25] and as the cause of single or
multiple spondylodiscitis with or without para-
verterbral abscesses [26–28].
B. capitatus may be the cause of funguria in
some patients [29].
Of all the possible pictures, the most common is
disseminated and multifocal infection which is
almost always diagnosed by the presence of
positive blood cultures in more than 90% of cases
[3,8,18,20–22,24–28,30–49].
Outside the context of the neutropenic patient,
there have been reports of cases of disseminated
infection by B. capitatus in an intravenous drug
user [48].
Laboratory
The diagnosis of invasive B. capitatus infection is
based on its isolation from normally sterile
organic ﬂuids or tissues. As mentioned above,
the fungus grows by forming white to cream-
coloured colonies, which are yeast-like, wrinkled,
shiny or opaque in appearance. Microscopy
reveals well-developed hyphae and pseudohy-
phae with aneloconidia and blastospores. Fer-
mentation tests are negative and the fungus only
assimilates glucose and galactose. The micro-
organism is urease-negative and resistant to
cycloheximide and capable of growing at 42 C
[1,50].
Unlike Trichosporon beigelii, there are no cross-
reactions with the latex test for the detection of
cryptococcal antigen [8] in patients infected with
B. capitatus.
Data on in-vitro sensitivity tests are somewhat
sparse in the literature; they are usually per-
formed with a low number of strains and they
occasionally provide contradictory and variable
information. in-vitro, the micro-organism is usu-
ally sensitive to amphotericin B and 5-ﬂucytosine
[24] and more variable to ﬂuconazole and other
azole derivatives [2,32,44,51].
A sensitivity study of six strains of B. capitatus
isolated in Spain revealed the following values of
the minimum 50% and 90% inhibition concen-
trations (MIC50 and MIC90): amphotericin B (0.25
and 0.50, respectively), ﬂuconazole (2 and 8),
itraconazole (0.06 and 0.25), ketoconazole (0.06
and 0.25) and 5FC (< 0.03 and > 64). In another
Fig. 1. Hepatic lesions caused by Blastoschizomyces capita-
tus in a patient with leukaemia.
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study on the four strains causing invasive disease
in our centre, the MICs were as follows: ampho-
tericin (2 lg ⁄mL), ﬂuconazole (32 lg ⁄mL),
5-ﬂucytosine (0.12–0.25 lg ⁄mL), ketoconazole
(0.5–1 lg ⁄mL), itraconazole (0.5–1 lg ⁄mL) and
voriconazole (0.12–0.5 lg ⁄mL) [18] (Table 1).
Among the new drugs, voriconazole has shown
good activity in-vitro against B. capitatus, but
there is no information on caspofungin as it is
difﬁcult to obtain suitable powder from the
manufacturer to carry out in-vitro tests [52].
Sordarins have shown good in-vitro activity
against B. capitatus [53,54].
In some patients, despite in-vitro sensitivity,
disease may occur even after prophylaxis with
different antifungal drugs [39,45].
Immunoblots enable us to detect the presence of
antibodies both in infected patients and in control
patients [55], and are therefore not considered very
useful from a diagnostic point of view.
Treatment and outcome
The outcome of invasive disease caused by
B. capitatus depends mainly on patient immunity.
In patients with profound neutropenia, mortality
is greater than 90% and survival has largely
coincided with the recovery of the neutrophil
count. The most common antifungal regimen to
date has been amphotericin B, either alone or
in association with other drugs, mainly with
5-ﬂucytosine. In isolated cases, the association of
neutrophils or neutrophils and macrophage-
stimulating factors, and the addition of treatment
with interferon-c, seem to be efﬁcacious, but the
evidence of their usefulness is totally inconclu-
sive [8,33,38]. In catheter-related infections, it is
essential to remove the catheter. When the disease




The ﬁlamentous fungus Scedosporium consists of
two species, S. proliﬁcans and S. apiospermum. Both
can cause invasive infections in immunocompro-
mised patients with a very poor prognosis.
Therapy of these infections is especially difﬁcult
because of their broad resistance to many anti-
fungal agents, including amphotericin B.
Scedosporium proliﬁcans
Severe fungal infections are especially common in
immunosuppressed patients, particularly in those
with prolonged neutropenia. Candida, Aspergillus
and zygomycetes are the most frequently encoun-
tered micro-organisms. However, new agents are
continuously being included in the list of oppor-
tunistic fungal pathogens [50]. S. proliﬁcans is the
most common cause of disseminated phaeohyp-
homycosis (infection caused by dematiaceous
fungi). A total of 30 cases have recently been
reviewed [56].
Micro-organism
S. proliﬁcans was ﬁrst described in 1984 by
Malloch and Salkin in a child with osteomyeli-
tis. It was then called S. inﬂatum and clear
identiﬁcation criteria were established some
years later. At present, S. proliﬁcans is preferred,
because of DNA similarities with Lomentospora
proliﬁcans [57]. Identiﬁcation is based mainly on
the morphological characteristics of the asexual
structures produced by the fungus in culture
(Fig. 2).
The organism is resistant to most antifungal
agents, including amphotericin B, 5-ﬂucytosine
and imidazoles [58]. New triazoles (UR-9825 and
voriconazole) have been found to have some
activity in-vitro [59], although these data have not
been conﬁrmed by other authors [60].
Epidemiology
S. proliﬁcans is a ubiquitous fungus present in soil.
Although its distribution is universal, most cases
have been reported in Spain and Australia
[56,61,62].
Table 1. In-vitro sensitivity data of four B. capitatus iso-
lates
Drug Dose Range MIC50 MIC90
AM B 2 lg ⁄mL 1–4 2 4
5-FC 8 lg ⁄mL 0.12–0.25 0.12 0.25
KETO 1 lg ⁄mL 0.5–1 1 1
FLU 16 lg ⁄mL 16–32 32 32
ITRA 0.25 lg ⁄mL 0.5–1 1 1
VORI – 0.12–0.5 0.25 0.5
LY-303366 – 1–4 4 4
AM B, amphtericin B; 5-FC, 5-ﬂucytosine; KETO, ketocon-
azole; FLU, ﬂuconazole; ITRA, itraconazole; VORI, voric-
onazole; anidulafungin.
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Most clinical cases are sporadic and may
appear both in immunocompetent and in immu-
nocompromised patients. The main risk factors in
immunocompetent patients are surgery and tra-
uma. In immunosuppressed patients, the most
important risk factor is prolonged profound
neutropenia [63–66]. Persistent neutropenia was
described in 90% of patients with disseminated
infection [56], and lung transplant, prosthetic
heart valve, and human immunodeﬁciency virus
(HIV) infection have also been reported as under-
lying conditions [56,65–67]. It may also colonise
the airway of patients with cystic ﬁbrosis [66].
Some small outbreaks have been reported [68–
70]. In one of the outbreaks, six inpatients with
acute nonlymphocytic leukaemia died as a result
of invasive infection with S. proliﬁcans. Phenoty-
pic and genotypic assessment of samples from
clinical material and ambient air from the isola-
tion rooms where the patients were being treated
showed that the epidemic was caused by a single
strain. After implementation of aerial control
measures, there were no further infections with
this organism [69]. In another report, the fungus
was recovered from the air in the room of a
patient with leukaemia and disseminated infec-
tion [71]. Fingerprinting by randomly ampliﬁed
polymorphic DNA analysis is a useful tool for the
analysis of possible outbreaks [72,73].
Clinical manifestations
In immunocompetent patients S. proliﬁcans may
cause locally invasive infections, which are usu-
ally osteoarticular and related to trauma or
surgery [61]. Cases of keratouveitis associated
with the intraocular long-term retention of a
contact lens [74] or pulmonary infection secon-
dary to long-standing bronchiectasis have also
been described [75].
The most common presentation of S. proliﬁcans
infection in immunocompromised patients is
fever unresponsive to broad-spectrum antimicro-
bial agents [61]. In many of the cases, the patients
were already receiving systemic antifungal agents
when the infection was diagnosed.
The infection may involve the lung, the skin
and almost every organ. Endophthalmitis, renal
and splenic abscesses, meningoencephalitis,
endocarditis and many other manifestations
have been reported [56,61,76]. In a recent series
from Spain, 37% of the patients had central
nervous system involvement and 25% had skin
lesions [61]. Skin lesions may appear as papular
rash, papules, or nodules that may become
necrotic.
Infection by S. proliﬁcans can be differentiated
from invasive aspergillosis by its higher tendency
to produce skin lesions and to be recovered from
blood cultures. Interestingly, 80% of dissemin-
ated infections with S. proliﬁcans were associated
with positive blood cultures [56]. The diagnosis
requires isolation in culture, since its histological
appearance is similar to that of Aspergillus.
Treatment
Focal infections in immunocompetent hosts
respond well to surgery and antifungal drugs,
but systemic S. proliﬁcans infection treatment is
difﬁcult. Optimal treatment of S. proliﬁcans infec-
tion remains controversial because of the resist-
ance of the micro-organism to practically all
available antifungal agents. Although many anti-
fungal agents have been used, no single drug was
associated with improved outcome.
At present, treatment involves amphotericin or
voriconazole, granulocyte colony-stimulating fac-
tor in neutropenic patients and surgical debride-
ment when feasible. Polymorphonuclear
leukocytes synergize with antifungal agents
against this micro-organism [77], so the reversal
of neutropenia may have important therapeutic
implications [78].
Some new approaches for the treatment of
infections caused by this micro-organism have
been studied. Terbinaﬁne has been shown to have
in-vitro activity against dematiaceous fungi. The
combination of terbinaﬁne and the azoles voric-
onazole, miconazole and itraconazole against ﬁve
clinical S. proliﬁcans isolates showed a synergistic
effect [79].
The in-vitro interaction between amphotericin
B and pentamidine against 30 clinical isolates was
evaluated using a checkerboard microdilution
Fig. 2. Flask-shaped annelloconidia of S. proliﬁcans form-
ing clusters at the ends of annellides with swollen bases
(lactophenol-cotton blue stain).
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method. Amphotericin B alone was inactive
against all the isolates. The combination was
synergistic against 28 out of 30 isolates (93.3–
100% depending on the method), and antagonism
was not observed [80].
Recovery from neutropenia is critical, and
mortality is essentially 100% in patients with
persistent neutropenia [56]. The disease is usually
rapidly fatal, and most patients die within 4 days
of the ﬁrst positive blood culture [61].
Scedosporium apiospermum
S. apiospermum is a saprophytic fungus isolated
worldwide from soil and plant residues.
Although the organism has shown low inherent
virulence, an increasing number of invasive infec-
tions caused by this micro-organism have been
reported in the last few years, mainly in patients
with haematological malignancies or solid organ
transplantation.
Micro-organism
S. apiospermum (the anamorph state of Pseudalle-
scheria boydii) is a hyaline ﬁlamentous fungus,
ubiquitously present in soil, sewage and polluted
waters.
P. boydii is characterised microbiologically by
terminal annelloconidia and characteristic cleist-
othecia in the sexual state (teleomorph form). The
asexual state (synanamorph) of P. boydii without
cleistothecia are designated S. apiospermum.
The fungus grows well on standard mycolog-
ical culture media. In a few days, the mould
colony takes on a tan colour and produces
characteristic sporulating structures. No serology
is available, although isolation of S. apiospermum
from a sterile site is diagnostic. The proportion of
positive blood cultures is much lower than for
S. proliﬁcans.
Regarding antimicrobial susceptibility, S. apio-
spermum isolates are more susceptible in-vitro than
S. proliﬁcans, with the highest activity exhibited
by voriconazole (MIC90, 0.5 lg ⁄mL), followed by
miconazole (MIC90, 1 lg ⁄mL), UR-9825 and pos-
aconazole (MIC90, 2 lg ⁄mL), and itraconazole
(MIC90, 4 lg ⁄mL). The MICs of terbinaﬁne,
amphotericin B and the two formulations of
nystatin (for which no statistically signiﬁcant
differences in antifungal activities were found
for the two species) for S. apiospermum isolates
were high. Cross-resistance was observed among
all the azoles except posaconazole, and among
all the polyenes except the lipid formulation [81].
Epidemiology
Invasive disease caused by S. apiospermum
has been described in solid organ transplant
recipients [67,82–88], patients with haemato-
logical malignancies [89], after haematopoietic
stem cell transplantation [90], in conjunction with
chronic corticosteroid therapy [91], and in
patients with HIV infection [92–94], nephritic
syndrome [95], or chronic granulomatous disease
[96,97] among others. Invasive mycoses after
near-drowning have been classically related to
this fungus [98].
Typing by polymerase chain reaction ampliﬁ-
cation of ribosomal intergenic spacer sequences
has been used in molecular epidemiological stud-
ies in patients with chronic lung disease [99].
The principal portal of entry is the respiratory
tract or the skin by trauma, from where it may
cause widespread dissemination.
Clinical manifestations
This micro-organism is an uncommon cause of
human infection. In normal hosts it usually
produces localised disease after penetrating trau-
ma or disseminated infection after aspiration of
polluted water. There have been reports of kera-
titis after trauma or surgery and even without
previous ocular injury [100–103], in conjunction
with chorioretinitis [104], vertebral osteomyelitis
[105], post-traumatic cranial infection [106],
lymphocutaneous syndrome [107], lymphadenitis
[108] and septic arthritis [109]. A case of dis-
seminated fatal disease after a post-traumatic
osteomyelitis has also been described [110].
S. apiospermum may also colonise the respiratory
tract of patients with cystic ﬁbrosis [111,112].
However, in immunocompromised patients it
may cause severe pulmonary or disseminated
infections. In patients undergoing continuous
ambulatory peritoneal dialysis it can cause pneu-
monia [83,93], mycetoma [113], sternal wound
infection [83], brain abscess [85,90,91,114,115],
sinusitis [94], endocarditis [116], skin lesions
[85,86,91,117–120], orchitis [87], malignant otitis
externa [92], fungemia [84], mycotic aneurysm
[121] and peritonitis [122]. Central nervous sys-
tem involvement is disproportionately common
in patients with pseudallescheriasis when com-
pared with many other mycoses.
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Many patients are already receiving systemic
antifungal therapy when the infection is diag-
nosed [90], with the result that it is described as
breakthrough mycoses.
Recently, 23 cases of solid organ transplant
patients have been reviewed [82]. The 23 patients
included liver (4), kidney (8), heart (8), lung (2),
and heart ⁄ lung (1) recipients. The disease was
more common inmales (19 : 4) andwas diagnosed
at a median of 4 months (range, 0.4–156 months)
after transplant. The clinical presentation included
disseminated disease (8), skin lesions (3), lung
disease (5), endophthalmitis (1), meningitis (1),
brain abscess with or without extension to the eye
(3), fungal mycotic aneurysm (1), and sinusitis (1).
Seven (30%) patients had intravascular infection,
and 11 (48%) patients had central nervous system
involvement. Antifungal therapy was accompan-
ied by surgical debridement in nine cases. Three
additional patients were found to have airway
colonisation only and received itraconazole pro-
phylaxis, without evidence of disease. Of 22
patients with known outcome, 16 (72.7%) died.
Five of six patients who survived had localised
infections: skin lesions (n ¼ 3), sinus fungus ball
(n ¼ 1), and solitary lung nodule (n ¼ 1). All
patients with disseminated disease and 10 of 11
patients with central nervous system disease died.
An exception was one patient with a brain abscess
who was successfully treated with voriconazole
and surgical drainage.
In a review of 31 reported cases of invasive
infection, 61% died despite antifungal therapy
[84]. Of eight patients with localised musculo-
skeletal soft tissue infection, seven required sur-
gery, and three underwent amputation.
The correct diagnosis of S. apiospermum infec-
tion must be conﬁrmed by the isolation of this
fungus in culture, since both its histological
appearance and clinical presentation are quite
similar to those of Aspergillus. A mistaken diag-
nosis can result in delayed or inappropriate
treatment, considering that S. apiospermum is
almost always resistant to amphotericin B. Micro-
biological diagnosis is easy, as a result of its
macro- and microscopic appearance in culture.
S. apiospermum should be included in the
differential diagnosis of any manifestation com-
patible with invasive mycosis in immunosuppre-
sed patients, mainly when treatment with
amphotericin B or itraconazole has failed.
Treatment
The management of invasive S. apiospermum
infections is difﬁcult because of this fungus’s
intrinsic resistance to many antifungal agents,
including ﬂuconazole and amphotericin B [123].
An early aetiologic diagnosis by culture is thus of
the utmost importance.
The treatment of choice for these infections has
not been established. Surgical resection, when
possible, and antifungal therapy with azole deriv-
atives (mainly itraconazole) have been successful
in some cases [97,124–126]. However, other
patients have shown no response to itraconazole
despite in-vitro susceptibility [127]. Most strains
are resistant to amphotericin B.
Miconazole has been used in some cases of
S. apiospermum infection [100]. However, consid-
ering the high toxicity of this compound, the
difﬁculty in obtaining intravenous miconazole
(not commercially available), and the high rate of
recurrence of infection and mortality, it is not
recommended at present.
Voriconazole is a new triazole with good
in-vitro activity against a range of moulds, inclu-
ding S. apiospermum [60]. The good in-vitro
activity and satisfactory experience in patients
after antifungal drug therapy mean that voricon-
azole is currently the drug of choice for this
infection [91,115,128–130].
Mellinghoff et al. have recently reported the
case of a 41-year-old man with acute lympho-
blastic leukaemia who developed multiple
S. apiospermum brain abscesses. The infection
progressed despite neurosurgical drainage and
treatment with itraconazole, amphotericin B and
ketoconazole, but the brain abscesses resolved
completely after treatment with posaconazole
alone [114]. New therapeutic options are being
explored [131]. Caspofungin may also have
in-vitro activity against this fungus [90].
The use of granulocyte colony-stimulating fac-
tors has been advocated as a potentially useful tool
in the treatment of very severe fungal infections,
even in non-neutropenic patients. It increases
neutrophil production and enhances polymorpho-
nuclear lymphocyte-mediated killing of fungal
pathogens in vivo, thereby implicating a possible
therapeutic role as a biological response-modifying
agent during opportunistic fungal infection. It
should be used for short-term treatments and in
very severe cases untilmore information is available.
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